What are the side effects of famotidine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Famotidine Side Effects

Famotidine is generally well-tolerated with common side effects including headache, dizziness, and constipation occurring in ≥1% of patients, but serious central nervous system reactions (confusion, delirium, hallucinations, seizures) can occur, particularly in elderly patients and those with renal impairment. 1

Common Side Effects (≥1% incidence)

Based on clinical trials of approximately 2,500 patients, the most frequent adverse reactions are 1:

  • Headache
  • Dizziness
  • Constipation

Less Common Side Effects (<1% in clinical trials)

Gastrointestinal

  • Nausea, vomiting, abdominal discomfort
  • Anorexia, dry mouth
  • Elevated liver enzymes 1

Neurologic/Psychiatric

  • Seizures
  • Hallucinations, depression, anxiety
  • Decreased libido, insomnia, somnolence 1

Cardiovascular

  • Palpitations 1

Other Systems

  • Musculoskeletal pain, arthralgia
  • Thrombocytopenia
  • Pruritus, dry skin, flushing
  • Tinnitus, taste disorder
  • Impotence 1

Serious Adverse Reactions

Central Nervous System Toxicity (Critical Warning)

CNS adverse reactions represent the most clinically significant risk with famotidine 1. These include:

  • Confusion, delirium
  • Hallucinations, disorientation
  • Agitation
  • Seizures
  • Lethargy 1

High-risk populations requiring particular vigilance 1, 2, 3:

  • Elderly patients (regardless of renal function)
  • Moderate renal impairment (CrCl 30-60 mL/min): 2-fold increase in drug exposure
  • Severe renal impairment (CrCl <30 mL/min): ≥5-fold increase in drug exposure
  • Neurosurgical patients: CSF/plasma ratio 4 times higher than non-neurosurgical patients (0.41-0.46 vs 0.12) 3

The mechanism involves excessive CNS accumulation due to reduced renal clearance, with documented toxic CSF concentrations of 160-249 ng/mL in symptomatic patients versus 47-85 ng/mL in asymptomatic patients with renal failure 3.

Postmarketing Serious Reactions

Life-threatening complications reported include 1:

  • Cardiovascular: Arrhythmia, AV block, prolonged QT interval
  • Hepatic: Cholestatic jaundice, hepatitis
  • Hematologic: Agranulocytosis, pancytopenia, leukopenia
  • Hypersensitivity: Anaphylaxis, angioedema
  • Musculoskeletal: Rhabdomyolysis
  • Respiratory: Interstitial pneumonia
  • Dermatologic: Toxic epidermal necrolysis/Stevens-Johnson syndrome

Pediatric-Specific Considerations

In infants and children, famotidine may cause 4:

  • Agitation or irritability (most common, including head-rubbing behavior in infants)
  • Somnolence
  • Anorexia
  • Headache
  • Vomiting

These effects occurred in 11 of 35 infants studied, with agitation/irritability being the predominant concern 4.

Cutaneous Manifestations

Recent case series identified acral macular skin lesions in COVID-19 patients receiving famotidine, which resolved completely upon drug discontinuation 5. While rare, this represents an emerging recognition of dermatologic reactions.

Clinical Pitfalls to Avoid

  1. Failure to dose-adjust in renal impairment: This is the single most important error leading to CNS toxicity. Mandatory dose reduction when CrCl <60 mL/min 1.

  2. Overlooking age as independent risk factor: Elderly patients are at increased CNS toxicity risk even with normal renal function 2.

  3. Misattributing CNS symptoms: In critically ill or postoperative patients, confusion/agitation may be incorrectly attributed to underlying illness rather than famotidine toxicity 3.

  4. Inadequate monitoring in high-risk groups: Neurosurgical patients require heightened surveillance due to dramatically increased CNS penetration 3.

Comparative Safety Profile

Famotidine demonstrates an excellent overall safety profile with only 0.43% of patients experiencing side effects in post-marketing surveillance 6. The drug does not interact with cytochrome P-450, avoiding the drug-drug interactions seen with cimetidine 6. However, this favorable profile applies primarily to patients with normal renal function and appropriate dosing.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.